Featured
Words by Yuriy Poteshkin, MD, phD
The year 2025 witnessed consolidation of CRISPR-Cas9 and AAV-mediated gene therapy as curative options for inherited blood disorders, with expanding clinical evidence for sickle cell disease,...
Words by Yuriy Poteshkin, MD, phD
The year 2025 marked a transformative period for incretin-based therapies, with glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GIP/GLP-1 agonist tirzepatide demonstrating...
Words by Yuriy Poteshkin, MD, phD
The dual GLP-1/GIP receptor agonist tirzepatide continued to demonstrate broad cardiometabolic benefits across multiple domains. The SURPASS-CVOT trial showed tirzepatide was noninferior to...
Words by Yuriy Poteshkin, MD, phD
A scoping review this week maps the design space of just-in-time adaptive interventions (JITAIs) for adult weight management and highlights a reality check: only a minority of studies use...
Words by Yuriy Poteshkin, MD, phD
A notable “upstreaming” trend this week: using endocrine physiology signals earlier in life to forecast later metabolic outcomes. An International Journal of Obesity mother–newborn–offspring study...
Words by Yuriy Poteshkin, MD, phD
Liquid biopsy through circulating tumor DNA (ctDNA) analysis matured as a powerful tool for minimal residual disease detection, treatment response monitoring, and early recurrence prediction across...
Words by Yuriy Poteshkin, MD, phD
Chimeric antigen receptor T cell (CAR-T) therapy and immune checkpoint inhibitors continued their evolution from hematologic malignancies toward solid tumors, with 2025 bringing significant advances...
Words by Yuriy Poteshkin, MD, phD
The ESCUDDO randomized trial demonstrated that a single dose of either bivalent or nonavalent human papillomavirus (HPV) vaccine provides equivalent protection against persistent cervical HPV...
Words by Yuriy Poteshkin, MD, phD
Liquid biopsy technology using circulating tumor DNA (ctDNA) emerged as a transformative biomarker-driven approach to personalized cancer therapy. The IMvigor011 trial demonstrated that ctDNA...
Words by Yuriy Poteshkin, MD, phD
Sodium-glucose cotransporter-2 (SGLT2) inhibitors emerged as foundational therapies for heart failure and chronic kidney disease regardless of diabetes status, with 2025 bringing definitive evidence...
Words by Yuriy Poteshkin, MD, phD
The ANDROMEDA-SHOCK-2 trial provided high-quality evidence for personalized hemodynamic resuscitation guided by capillary refill time (CRT) in early septic shock. This multicenter trial across 19...
Words by Yuriy Poteshkin, MD, phD
The 4D randomized clinical trial demonstrated that continuous intravenous dexmedetomidine significantly reduced the combined burden of agitation, delirium, and need for intubation in non-intubated...
Words by Yuriy Poteshkin, MD, phD
The microbiota-gut-brain axis emerged as a therapeutic target across neurodegenerative and neuropsychiatric conditions, with 2025 studies demonstrating that fecal microbiota transplantation,...
Words by Yuriy Poteshkin, MD, phD
The year 2025 witnessed the consolidation of anti-amyloid monoclonal antibodies as disease-modifying therapies for early Alzheimer's disease, with lecanemab and donanemab receiving widespread...
Words by Yuriy Poteshkin, MD, phD
The year 2025 witnessed consolidation of CRISPR-Cas9 and AAV-mediated gene therapy as curative options for inherited blood disorders, with expanding clinical evidence for sickle cell disease,...
Words by Yuriy Poteshkin, MD, phD
Artificial intelligence and machine learning emerged as powerful tools for early sepsis detection and risk stratification, with multiple 2025 studies demonstrating superior performance compared to...
Words by Yuriy Poteshkin, MD, phD
Large language models (LLMs), particularly GPT-4, ChatGPT, and emerging competitors, demonstrated clinically meaningful diagnostic accuracy across diverse medical specialties in 2025, marking a...
Words by Yuriy Poteshkin, MD, phD
Machine learning-derived clinical prediction models demonstrated superior performance compared to traditional statistical approaches across diverse applications, including surgical complication...
Words by Yuriy Poteshkin, MD, phD
Across this week’s diabetes/obesity literature, the AI/ML angle is less about “fancier models” and more about engineering better inputs (composite indices, multimodal biomarker sets) and then...
